Biontech Se Sponsored Adr Stock News

The South African Health Products Authority (SAHPRA) on Wednesday approved the use of Pfizer''s Comirnaty COVID vaccine after BioNTech and Pfizer announced that two doses of their vaccine may not be enough to protect against Omicron.

BioNTech and Pfizer said that a preliminary laboratory study demonstrated a three-shot course of their COVID-19 vaccine generates a neutralising effect against the new Omicron variant in a laboratory test.

As we learned from Schoolhouse Rock, three is a magic number. Pfizer/BioNTech says a total of three jabs of their vaccine is likely to protect against infection with the Omicron variant and that two doses may not be enough, according to new laboratory data that will increase pressure to speed up booster programs. Tests using The post Pfizer Recommends a Total of Three Vaccinations to Fend Off Omicron Variant appeared first on HillReporter.com .

BBC News: Pfizer and BioNTech have said a booster jab of their coronavirus vaccine promises to be an effective defence against the new Omicron variant. Three doses provide a similar level of antibodies against Omicron to that of two doses against other variants, the companies said after a small study. The World Health Organization (WHO) [] This article Pfizer Says Booster Shot Promising Against Omicron appeared first on St. Lucia Times News .

NEW YORK - Wall Street closed slightly higher on Wednesday with the three major indexes managing their third straight day of gains after test data showed the COVID-19 vaccine from Pfizer and BioNTech offered some protection against the new Omicron variant. Pfizer and BioNTech said their three-shot course of the vaccine was able to neutralize the Omicron variant in a laboratory test and they could deliver an upgraded vaccine in March 2022 if needed. Investors reacted by piling into travel related stocks. The S&P 1500 Airlines index closed up 1.96%. Its session high was the highest since Nov. 24, which was just before news of the variant emerged. Market Keep on reading: Wall Street closes higher as vaccine update feeds optimism

Preliminary laboratory studies demonstrate that three doses of the Pfizer/BioNTech COVID-19 Vaccine neutralize the Omicron variant while two doses show significantly reduced neutralization titers, the American and German vaccine developers said in a joint statement

Investors were weighing a good news/bad news update about the coronavirus vaccine co-developed by the biotech.

Bonds Bloodbath, Dollar Dumped As Omicron Anxiety Ebbs & Flows Anxiety over Omicron was higher overnight from South African data showing Pfizer vaxx efficacy weakened against Omicron but then the CEO of the company that makes billions from the vaccine - and is protected from any liabilities - said, all you need is a 3rd jab and that will save you all from Omicron... and the market rejoiced. Small Caps outperformed today but traded in a truly chaotic manner. The Dow ended the day unchanged-ish and S&P and Nasdaq modestly higher... Notably, the major US equity indices remain unable to extend gains above pre-Omicron levels... ''Recovery'' stocks continue to charge higher relative to ''Stay at Home'' stocks... Source: Bloomberg Despite all the jawboning, Pfizer, BioNtech and Moderna are all down on the week... Source: Bloomberg Bond yields exploded higher today (amid a very heavy calendar). 30Y Yields are up 20bps this week while 2Y is only up 8bps... Source: Bloomberg 30Y Yields remain well below 2.00% (pre-Omicron) levels, but today was a decent squeeze to say the least as 30Y spiked over 13bps from low to high yield...

BioNTech and Pfizer said on Wednesday a three-shot course of their COVID-19 vaccine was able to neutralize the new Omicron variant in a laboratory test and they could deliver a vaccine targeted at it in March 2022 if needed. Francis Maguire reports.

BioNTech and Pfizer said on Wednesday a three-shot course of their COVID-19 vaccine was able to neutralize the new Omicron variant in a laboratory test and said they could deliver an upgraded vaccine in March 2022 if needed.

Two shots are insufficient, but three doses of the Covid-19 vaccine developed by Pfizer and BioNTech effectively neutralise the Omicron coronavirus variant, the companies stated on the basis of their own laboratory tests. According to Pfizer/BioNTech, three shots provide as much protection against the Omciron variant as two shots do against other variants. Fully vaccinating []

Good news about a booster dose with the omicron variant could be bad news for the biotech''s future sales.

SOURCE: BBC- Pfizer and BioNTech have said a booster jab of their coronavirus vaccine promises to be an effective defence against the new Omicron variant. Three doses provide a similar level of antibodies against Omicron to that of two doses with other variants, the companies said after a small study. The World Health Organization (WHO) [] The post WORLD: Pfizer says booster shot promising against Omicron appeared first on Barbados Today .

Pfizer and BioNTech have said three doses of their Covid-19 vaccine is able to neutralise the new Omicron Covid-19 variant. The companies said they could deliver a vaccine tailored for the Omicron variant by March 2022. They said two doses of their vaccine resulted in significantly lower neutralising antibodies, but a third dose increased the []